Monitor the June 22 conference call for actual efficacy/safety data from the BESTOW trial. Stock may move on data quality, not on this announcement.
Price Chart
Executive Summary
Eledon Pharmaceuticals will present new clinical data from its tegoprubart Phase 2 BESTOW trial and extension study at the American Transplant Congress in June 2026. No actual results are disclosed in this announcement; the event is a routine pipeline update for a clinical-stage biotech.
Key Facts
- Oral and poster presentations at ATC (June 20–24, 2026) covering tegoprubart in kidney transplantation
- Investor conference call scheduled for June 22, 2026 at 8:00 AM ET to discuss the data
Financial Impact
No financial impact disclosed; pure data disclosure event
Risk Factors
- Clinical trial data may disappoint, leading to negative stock reaction
- Competition from other anti-CD40L antibodies or standard-of-care immunosuppressants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298862 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $2.89 $2.26 | ▼ −21.97% | ▼ −21.41% | $2.21 (−23.53%) |
Sep 22, 2026 4w ago | Press Release | $2.89 $2.26 | ▼ −21.97% | ▼ −21.41% | $2.21 (−23.53%) |
May 20, 2026 22w ago | Press Release | $3.89 $3.82 | ▼ −1.93% | ▼ −2.26% | $2.21 (−43.19%) |
Mar 10, 2026 32w ago | Press Release | $2.90 $3.13 | ▲ +7.93% | ▲ +8.09% | $2.21 (−23.79%) |
Feb 28, 2026 34w ago | Institutional Cluster | $2.66 $2.71 | ▲ +1.88% | ▲ +9.82% | $2.21 (−16.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers